MDxHealth acquires Oncotype DX prostate test from Exact Sciences

Aug. 02, 2022 6:54 PM ETExact Sciences Corporation (EXAS), MDXHBy: Jonathan Block, SA News Editor2 Comments

Prostate Cancer Slide


  • MDxHealth SA (NASDAQ:MDXH) has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences (NASDAQ:EXAS) as well as the latter's urology sales and marketing team.
  • Under the deal, MDxHealth (MDXH) paid $25M in cash, plus another $5M worth of American Depository Shares. Exact Sciences (EXAS) can also receive up to an additional $70M based on revenue milestones in fiscal years 2023 through 2025.
  • MDxHealth is financing the acquisition through a $35M loan with an affiliate of Innovatus Capital Partners. An additional $35 million can be drawn from Innovatus through a $20M term B loan and a $15 million term C loan in, respectively, 2024 and 2025.
  • After Tuesday's closing bell, Exact Sciences' (EXAS) Q2 2022 results beat on the top and bottom lines though the company lowered its full-year guidance.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.